Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
GILEAD Sciences' acquisition of Kite Pharma has brought it back to a familiar - and contentious - dilemma: How much should a drugmaker charge for a novel drug that has the potential to cure a disease?
Back in 2013, Gilead was battered by public outrage when it priced its...